Analytical Data
-
Gene name
LRIG3
- Application
-
Alternative Names
LIG3
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6P1C6
-
Expression Region
Asp866~Cys1110
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LRIG3 is a member of the LRIG (leucine-rich repeats and immunoglobulin-like domains) family of proteins, which are known to play significant roles in regulating cell signaling pathways, particularly those involved in growth factor receptor activity. Specifically, LRIG proteins interact with receptor tyrosine kinases (RTKs) and are implicated in modulating cellular responses to various stimuli, influencing processes such as cell proliferation, differentiation, and survival. The study of LRIG3, which is primarily expressed in the nervous system and certain tissues, has garnered attention due to its potential involvement in cancer biology and neurodevelopmental disorders. Several studies have suggested that LRIG3 may act as a tumor suppressor by inhibiting excessive RTK signaling, thereby contributing to the regulation of cellular homeostasis. Additionally, alterations in LRIG3 expression have been associated with various malignancies, making it a potential biomarker for cancer diagnosis and prognosis. Given the growing interest in targeted therapies that exploit these molecular pathways, understanding the structure and function of LRIG3 through recombinant protein expression becomes critical. Research focusing on the recombinant expression of LRIG3 allows for a more detailed investigation of its functional roles and interactions within the cellular context, potentially revealing novel therapeutic targets or strategies for diseases related to dysregulated signaling pathways.
